A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

NCT00267007 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

32

Enrollment

INDUSTRY

Sponsor class

Stopped Slow enrollment

Conditions

Peripheral Neuropathy, Chemotherapy-induced

Interventions

DRUG: PROCRIT 40,000 IU QW
DRUG: Placebo

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators

[object Object]